The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1701
April 29, 2024
View Complete Issue         Table of Contents 2019 
A New Indication for Semaglutide (Wegovy)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A New Indication for Semaglutide (Wegovy)
April 29, 2024 (Issue: 1701)
The injectable glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Wegovy) has been approved by the FDA to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease (CVD) and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A New Indication for Semaglutide (Wegovy)
Article code: 1701b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.